CA 15-3 Assay
Order Name
CA15-3
Test Number: 2024000
Revision Date 10/28/2025
Test Number: 2024000
Revision Date 10/28/2025
| Test Name | Methodology | LOINC Code |
|---|---|---|
|
CA 15-3 Assay
|
Chemiluminescence Assay | 6875-9 |
| SPECIMEN REQUIREMENTS | ||||
|---|---|---|---|---|
| Specimen | Specimen Volume (min) | Specimen Type | Specimen Container | Transport Environment |
| Preferred | 2mL (1mL) | Serum | Clot Activator SST | Refrigerated |
| Alternate 1 | 2mL (1mL) | Plasma | Lithium Heparin PST (Light Green Top) | Refrigerated |
| Instructions | Separate from cells within 2 hours after collection. Stability: Ambient 1 day. Refrigerated 7 days. Frozen > 7 days. |
|||
| GENERAL INFORMATION | |
|---|---|
| Testing Schedule | Mon - Fri |
| Expected TAT | 1-3 days |
| Clinical Use | Measurements of CA 15-3 in women with treated carcinoma of the breast may be useful for predicting early recurrence. The FDA has approved CA 15-3 for serial testing in women with prior stage II or III breast cancer who are clinically free of disease. |
| Notes | Testing performed via Abbott Alinity Immunoassay method. Results obtained with different assay methods should not be used interchangeably in serial testing. It is recommended that only one assay method be used consistently to monitor each patient's course of therapy. |
| CPT Code(s) | 86300 |
| Service Provided By |  |
| Lab Section | Chemistry |